Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
114.00    2.50 (2.24%)
Bid:
112.00
Ask:
116.00
Spread: 4.00 (3.571%)
Market Cap: £68.59m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

7 Oct 2009 07:00

RNS Number : 3501A
Intercede Group PLC
07 October 2009
 



7 OCTOBER 2009

INTERCEDE GROUP plc

("Intercede" or "the Company")

Trading Update

Intercede, a leading producer of Identity and Credential Management Systems (IDCMS) software, today announces excellent progress in the six months ended 30 September 2009.

Sales for the first half of the current financial year are more than 40% higher than for the comparable period last year. The Directors are also pleased to report that the Company has strongly increased its operating profit before exceptional items during the period.

The growth in sales is especially encouraging, because it is based both on existing customers expanding deployments installed in earlier periods and on new licence sales into new markets for actual end-customer projects. As a result, we are now experiencing a return on the investment made in development and sales efforts in previous years. Our expansion into new sectors and territories is also producing a fresh and immediate stream of revenue. This is evidence of the ongoing strength and viability of Intercede's business model and of a strategy that is being successfully executed. 

Key achievements during the period include:

Maintaining and expanding existing major projects for Lockheed MartinUK Government, US Federal Government, NHS and others. 

Winning new contracts to supply MyID to customers in AustraliaAustriaCzech RepublicRomaniaSlovakiaSwitzerland and the US.

Deploying MyID systems at a major security printing and smart card manufacturer, at a major Scandinavian bank and within a European government agency.

Adding the US Social Security Administration to Intercede's Federal HSPD-12 customer list. 

Further details will be provided when Intercede announces its Interim Results for the six months ended 30 September 2009, which is expected to take place in December 2009.

The reported period includes exceptional costs for defending a previously reported patent infringement case in the US filed by ActivIdentity Corporation. Intercede's answer and counterclaims deny that its products infringe ActivIdentity's patent and allege further that this patent is invalid and unenforceable. In addition, Intercede has filed counterclaims against ActivIdentity, including alleging violations of US antitrust law. The court recently rejected ActivIdentity's challenge to Intercede's antitrust claims and one basis for a declaration of unenforceability. While the court dismissed other counterclaims alleging fraudunfair competition, and an additional basis for a declaration of unenforceability, it gave Intercede the right to re-plead those claims with more factual detail. Intercede filed its amended counterclaims on 28 September 2009. Intercede intends to pursue its defence and its counterclaims vigorously. 

Costs and cash collections have also been kept under control throughout the period, as evidenced by a half year cash balance of £3,913,00, compared to £3,711,000 at 31 March 2009 and £1,839,000 at 30 September 2008. The cash position as at 30 September 2009 is thus more than double that of a year ago, notwithstanding the legal costs incurred to date in defending the patent infringement case brought by ActivIdentity and in pursuing the Company's counterclaims against ActivIdentity. 

Richard ParrisIntercede's Chairman and Chief Executive, said:

"Our order book indicates that Intercede is on track to continue our planned growth trajectory for this year and beyond. I am delighted that our sales pipeline is stronger than ever and that a number of our existing larger projects are set to exceed expectations in terms of future growth. In particular our entry into the national identity market is proving to be particularly rewarding while our partnerships with Lockheed Martin, Thales and VeriSign are making continuing and growing contributions to operating profit."

About Intercede 

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management. Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a programme with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

Intercede and MyID are registered trademarks or trademarks in the UK, US and/or other countries. 

For more information visit http://www.intercede.com.

ENQUIRIES

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

FinnCap

Charles Cunningham

Tel. +44 (0)20 7600 1658

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7337 1509

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRFSMFMMSUSEFS
Date   Source Headline
6th Nov 20147:00 amRNSShare Buyback Programme
6th Nov 20147:00 amRNSHalf Yearly Report
7th Oct 20147:00 amRNSTrading Update
29th Sep 20147:00 amRNSFirst Customer: Derived Credentials for Mobile
17th Sep 20144:25 pmRNSResult of AGM
1st Aug 20147:00 amRNSShare Incentive Plan
26th Jun 20149:37 amRNSDirector/PDMR Shareholding
25th Jun 20141:20 pmRNSDirector Share Dealings
10th Jun 20147:00 amRNSDirector Share Dealings
5th Jun 20147:00 amRNSFinal Results
6th May 201410:32 amRNSShare Incentive Plan
1st Apr 20147:00 amRNSDirectorate Change
27th Mar 20147:00 amRNSTransaction in Own Shares
25th Mar 201410:35 amRNSTransfer of Treasury Shares
20th Mar 20147:00 amRNSTransaction in Own Shares
13th Mar 20147:00 amRNSShare Incentive Plan
13th Mar 20147:00 amRNSTransfer of Treasury Shares
4th Mar 20149:09 amRNSTransaction in Own Shares
27th Feb 20147:00 amRNSTransaction in Own Shares
13th Feb 20147:00 amRNSTransaction in Own Shares
7th Feb 20147:00 amRNSPartnership with TELUS and Gemalto
5th Feb 20147:00 amRNSTransaction in Own Shares
28th Jan 201411:30 amRNSTransaction in Own Shares
13th Jan 20147:00 amRNSShare Buyback Programme
8th Jan 20147:00 amRNSTrading Update
10th Dec 20136:00 pmRNSDirector Share Dealings
10th Dec 20134:49 pmRNSDirector Share Dealings
21st Nov 20137:00 amRNSHalf Yearly Report
5th Nov 20137:00 amRNSNew Contract Win
1st Oct 20137:00 amRNSDirector Share Dealings
26th Sep 20137:00 amRNSDirector/PDMR Shareholding
25th Sep 20131:00 pmRNSResult of AGM
25th Sep 20137:00 amRNSContract Wins and AGM Statement
9th Sep 20137:00 amRNSDirectors' Holding
29th Jul 20137:00 amRNSContract awards and Trading update
17th Jun 20137:00 amRNSDirector/PDMR Shareholding
4th Jun 20137:00 amRNSFinal Results
25th Apr 20137:00 amRNSContract Win
16th Apr 20137:00 amRNSAppointment of Non-Executive Director
5th Apr 20137:00 amRNSYear end trading update
1st Feb 20137:00 amRNSTrading Update
3rd Dec 20127:00 amRNSHolding(s) in Company
22nd Nov 20127:00 amRNSInterim Results
4th Oct 20127:00 amRNSTrading Update
26th Sep 20124:39 pmRNSResult of AGM
21st Aug 20127:00 amRNSAmendments to LTIP
4th Jul 20123:35 pmRNSDirector/PDMR Shareholding
14th Jun 20122:37 pmRNSIssue of Equity
12th Jun 201210:13 amRNSDirector/PDMR Shareholding and Issue of equity
5th Apr 20127:00 amRNSYear End Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.